Active substanceMethyl ethylpyridinolMethyl ethylpyridinol Similar drugsTo uncover Cardiocipine solution d / infusion BIOSINTEZ, PAO Russia Cardiocipine solution w / m in / in BIOSINTEZ, PAO Russia Methyl ethylpyridinol solution for injections ATOLL, LLC Russia Methyl ethylpyridinol solution for injections ELLARA, LTD. Russia Methyl ethylpyridinol solution for injections Company DEKO, LLC Russia Methyl ethylpyridinol-Eskom solution for injections ESKOM NPK, OAO Russia Emoticon Optics drops d / eye SYNTHESIS, JSC Joint-stock Kurgan Society of Medical Preparations and Products Russia Emoxibel solution d / infusion Emoxibel solution for injections BELMEDPREPARATY, RUP Republic of Belarus Emoxibel drops d / eye BELMEDPREPARATY, RUP Republic of Belarus Emoxibel solution w / m in / in BELMEDPREPARATY, RUP Republic of Belarus Emoxipine® drops d / eye MOSCOW ENDOCRINE FACTORY, FSUE Russia Emoxipine solution w / m in / in MOSCOW ENDOCRINE FACTORY, FSUE Russia Emoxipine drops d / eye FARMENT FIRM, LLC Russia Emoxipine solution for injections MOSCOW ENDOCRINE FACTORY, FSUE Russia Emoxipine-AKOS drops d / eye SYNTHESIS, JSC Joint-stock Kurgan Society of Medical Preparations and Products Russia Emoxipine-Acti solution d / infusion Aktifarm, OOO Russia Dosage form: & nbspInjection. Composition:1 ml of the solution contains:Active substance: Methyl ethylpyridinol hydrochloride (emoxipin) - 10 mg; Excipients: Hydrochloric acid OD M, water for injection. Description:Transparent colorless liquid. Pharmacotherapeutic group:Antioxidant. ATX: & nbspS.01.X.A Other drugs for the treatment of eye diseases Pharmacodynamics:Antioxidant. Emoksipin reduces the permeability of the vascular wall, is an inhibitor of free radical processes, an antihypoxant and an antioxidant. Reduces blood viscosity and platelet aggregation, increases the content of cyclic nucleotides (cyclic adenosine monophosphate and cyclic guanosine monophosphate) in platelets and brain tissue, has fibrinolytic activity, reduces the permeability of the vascular wall and the risk of developing hemorrhages, contributes to their resorption. Expands coronary vessels, in the acute period of myocardial infarction limits the magnitude of the focus of necrosis, improves the contractility of the heart and the function of its conductive system. At high arterial pressure has an antihypertensive effect.In acute ischemic impairment of cerebral circulation reduces the severity of neurologic symptoms, increases tissue resistance to hypoxia and ischemia.It has retinoprotective properties, protects the retina from the damaging effect of high-intensity light, promotes resorption of intraocular hemorrhages, improves microcirculation of the eye. Indications:Subconjunctival and intraocular hemorrhage of various genesis; Angioretinopathy (including diabetic retinopathy);Central and peripheral chorioretinal dystrophy;Thrombosis of the central vein of the retina and its branches;Complications of myopia;Angiosclerotic macular degeneration (dry form);Operative interventions on the eyes, condition after surgery for glaucoma with detachment of the choroid;Dystrophic diseases of the cornea;Injury, inflammation and burn of the cornea;Protection of the cornea (when wearing contact lenses) and the retina of the eye from exposure to high-intensity light (laser and sunburn, with laserocoagulation). Contraindications:- Increased individual sensitivity to the drug;- Pregnancy, lactation;- Children under 18 years. Dosing and Administration:Emoxipia solution is administered subconjunctivally or parabulbarically. If necessary, retrobulbar injection is possible. Subconjunctivally enter 0.2-0.5 ml (2-5 mg), parabulbar - 0.5-1 ml (5-10 mg) solution of the drug. Emoksipin applied once a day or every other day for 10-30 days. If necessary, treatment can be repeated 2-3 times a year. Retrobulbarno inject 0.5-1 ml of the drug solution once a day for 10-15 days.For protection of the retina in lacerocoagulation (including with limiting and destructive coagulation of tumors), parabulbar or retrobulbno for 0.5-1 ml of the drug solution for 24 hours and 1 hour prior to coagulation; then in the same doses (0.5 ml of solution) once a day for 2-10 days. Side effects:Short-term excitation, drowsiness, increased blood pressure, allergic reactions (skin rashes, etc.), local reactions - pain, burning, itching, hyperemia, densification of paraorbital tissues (resolves itself). Interaction:Pharmaceutically incompatible with other medicines. Special instructions:Treatment should be carried out under the control of blood pressure and blood coagulability. Form release / dosage:Solution for injection 10 mg / ml. Packaging:1 ml per ampoule of neutral glass grade HC-1 or HC-3 or imported.5 ampoules per contour cell packaging made of polyvinylchloride film and foil of aluminum printed lacquered or flexible packaging on the basis of aluminum foil or without foil.For 1 or 2 contour mesh packages (with foil or without foil) with instruction on the use of the preparation, with a knife or scapegrator ampoule in a pack of cardboard.For 20, 50 or 100 contour cell packs (with foil) with 20, 50 or 100 instructions for the use of the drug, respectively, with knives or scarifiers ampouled into a cardboard box or into a box of corrugated cardboard (for inpatient).When packing ampoules with notches, rings and break points, knives or scarifier ampoules do not. Storage conditions:In the dark place at a temperature of no higher than 25 ° C.Keep out of the reach of children. Shelf life:3 years. The drug should not be used after the expiration date. Terms of leave from pharmacies:On prescription Registration number:P N001173 / 01 Date of registration:09.04.2008 / 14.01.2013 Expiration Date:Unlimited The owner of the registration certificate:MOSCOW ENDOCRINE FACTORY, FSUE MOSCOW ENDOCRINE FACTORY, FSUE Russia Manufacturer: & nbspMOSCOW ENDOCRINE FACTORY, FSUE Russia Information update date: & nbsp2016-08-28 Illustrated instructions × Illustrated instructions Instructions